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Background: Most head and neck (H&N) cancer patients receive high-dose external beam radiation therapy (RT), often
in combination with surgery and/or chemotherapy. Unfortunately, high-dose RT has significant adverse effects on the
oral and maxillofacial tissues, some of which persist for the life of the patient. However, dental management of these
patients is based largely on individual and expert opinion, as few studies have followed patients prospectively to
determine factors that predict adverse oral sequelae. In addition, many previous studies were conducted before wide-
spread adoption of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy. The objective of this
multi-center study is to systematically evaluate the oral health of subjects for 2 years after commencement of RT, with
the goal of identifying risk factors that predict adverse oral outcomes post-RT.
Methods: This is a prospective multi-center longitudinal cohort study of H&N cancer patients who receive high-dose RT
with curative intent. Planned enrollment is 756 subjects at 6 primary clinical sites (and their affiliated sites) in the USA. A
baseline visit is conducted prior to the beginning of RT. Follow-up visits are conducted at 6, 12, 18 and 24 months from
the start of RT. The primary outcome measure is the 2-year rate of tooth loss in patients who have received at least one
session of external beam RT for H&N cancer. Secondary outcome measures include the incidence of exposed intraoral
bone; incidence of post-extraction complications; change in Decayed Missing and Filled Surfaces (DMFS);
change in periodontal measures; change in stimulated whole salivary flow rates; change in mouth opening;
topical fluoride utilization; chronic oral mucositis incidence; changes in RT-specific quality of life measures; and
change in oral pain scores.
Discussion: This study will contribute to a better understanding of the dental complications experienced by
these patients. It will also enable identification of risk factors associated with adverse outcomes such as tooth
loss and osteoradionecrosis. These findings will support the development of evidence-based guidelines and
inform the planning of future interventional studies, with the goal of advancing improvements in patient care
and outcomes.
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Most head and neck (H&N) cancer patients receive
high-dose external beam radiation therapy (RT), often in
combination with surgery and/or chemotherapy [1].
Unfortunately, high-dose RT has significant adverse ef-
fects on the oral and maxillofacial tissues, some of which
persist for the life of the patient [2]. The salivary glands
are often included in the fields of radiation, which fre-
quently leads to irreversible hyposalivation [3], resulting
in increased rates of dental caries and tooth loss post-
radiation [4]. Radiation-induced soft tissue fibrosis can
lead to restricted mouth opening (trismus), which
reduces the ability to maintain oral hygiene [5]. Further-
more, radiation impairs bone homeostasis and ability to
heal, leading to a life-long risk of jaw osteoradionecrosis
(ORN), which is often precipitated by dental extractions
[6]. Consequently, these patients are caught in a vicious
circle, being at higher risk of needing dental extractions,
but with extractions to be avoided post-RT due to the
risk for ORN.
To attempt to reduce the frequency of such complica-
tions, pre-RT dental evaluation and management is con-
sidered a best practice and standard of care in the USA
and many other countries. However, pre-RT dental man-
agement practices vary widely among centers, due to a
lack of reliable data on dental morbidity in these patients
and on outcomes of dental management strategies. Al-
though some studies indicate that these patients have
significant dental morbidity post-RT, definitive data to
document the extent, severity and risk factors for these
complications do not exist. Consequently, pre-RT dental
management is largely based on expert opinion [7]. For
example, an international survey of dentists/oral sur-
geons experienced in providing pre-RT care found that
approximately 50% would extract a mandibular tooth in
the radiation field with a small periapical lesion and pain
on percussion, while 50% would treat the tooth end-
odontically [8]. Clinicians mentioned that the lack of ad-
equate data reduced their confidence in their treatment
decisions. Such disparate decision-making can result in
sub-optimal dental and medical outcomes for these
complex patients.
The objective of this prospective observational cohort
study is to collect data on dental outcomes in patients
who have received RT to the H&N region. Systematic
collection of this data in a large multi-center cohort will
lead to a better understanding of the dental complica-
tions experienced by these patients. In addition, it will
enable the identification of risk factors associated with
negative outcomes such as tooth loss and ORN. These
findings will support the development of evidence-based
guidelines and should lead to improvements in patient
care and outcomes. The purpose of this manuscript is to
describe the study protocol (version 4, 29 October 2015)for this important ongoing study and provide insight
based on our experience related to subject recruitment
and complexity of study procedures.
Methods
Study design
This is a prospective multi-center longitudinal cohort
study of H&N cancer patients who receive high-dose RT.
Outcome measures
The primary outcome measure is the 2-year rate of tooth
loss in patients who have received at least one session of
external beam RT with curative intent for H&N cancer.
“Tooth loss” is defined as a dental extraction that has
been performed or recommended. Teeth that are lost
without the involvement of a healthcare professional are
also included in this definition. Since dental extractions
are often avoided in this population because of the in-
creased risk of ORN, tooth loss also includes teeth hav-
ing a dental procedure to avoid extraction of a tooth
that would have been extracted if the individual had not
received RT. The following categories constitute teeth
that would otherwise be recommended for extraction:
non–restorable because of fracture or extent of caries;
amputated crown with root remaining; uncontrolled or
persistent periodontal or odontogenic infection. Such
teeth are classified as “hopeless teeth” for the purposes
of this study.
Secondary outcome measures include the following
additional oral health outcomes associated with RT in
H&N cancer patients and potential risk factors for nega-
tive outcomes:
 Incidence of exposed intraoral bone, suggestive of
ORN. This will be defined as exposed maxillary or
mandibular bone with an avascular appearance in a
quadrant that has received RT;
 Incidence of post-extraction complications;
 Change in Decayed, Missing, and Filled Surfaces
(DMFS);
 Change in periodontal measures;
 Change in stimulated whole salivary flow rates;
 Change in mouth opening in mm;
 Use of fluoride to prevent new caries;
 Incidence of chronic oral mucositis;
 Change in RT-specific quality of life measures; and
 Change in pain scores as measured with the UCSF
Oral Cancer Pain Scale.
Study organization and funding
Subjects are enrolled at six primary clinical study sites,
which are (in alphabetical order): Brigham and Women’s
Hospital, Carolinas Medical Center, New York University,
University of Connecticut Health, University of North
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each site include the site Principal Investigator (PI), study
coordinator(s), and clinical examiner(s). Some of the pri-
mary clinical sites have also established local affiliated
sites. The Data Coordinating Center (DCC) for the study
is located at the University of Minnesota (Division of Bio-
statistics) and includes the site PI/study statistician, study
manager, and database administrator. The study is funded
by the US National Institute for Dental and Craniofacial
Research (NIDCR) through a cooperative agreement
(U01) mechanism. NIDCR staff are closely involved in the
development and oversight of the study.
Safety of human subjects and data integrity
Approval from the Institutional Review Board (IRB) at
each clinical study site was obtained before beginning
enrollment at that site. Any changes are also communi-
cated to IRB and other stakeholders as appropriate. In
addition, each site was individually activated by the
NIDCR after passing all relevant requirements for hu-
man subjects safety and personnel training. All subjects
participate in an informed consent process conducted by
the study coordinator, including the signing of a written
informed consent document. An independent Data and
Safety Monitoring Board (DSMB) has been constituted
by the NIDCR to ensure subject safety. It has 3 mem-
bers, all of whom are free from competing interests. It
meets annually and additional meetings can be called as
needed. The DSMB reviews any adverse events as well
as other study data. No safety concerns have been identi-
fied to date.
Study data is entered into a secure database, hosted at
the DCC, using web-based data-entry screens created
for this study. DCC staff monitor study data to identify
missing data or forms and communicate with the clinical
sites to resolve these issues. Formal monitoring of study
records is conducted by an independent contract re-
search organization. Study Monitors visit each clinical
site annually for formal study monitoring.
Training and calibration
All study personnel receive training on the activities they
conduct in the study. This includes training on carrying
out clinical assessments as well as training on complet-
ing study forms, data entry, and all non-clinical proce-
dures. In addition, annual in-person calibration on
healthy volunteers is conducted for all clinical examiners
for DMFS and periodontal measurements. Clinical ex-
aminers must meet minimum standards for intra- and
inter-rater consistency annually for these measurements.
Specifically, examiners must achieve at least 95% intra-
examiner reproducibility within ± 2 mm for both clinical
attachment loss and pocket depth; at least 75% inter-
examiner agreement for pocket depth within ± 1 mm;and at least 60% inter-examiner agreement for clinical
attachment loss within ± 1 mm. Examiners also receive
hands-on training on measuring furcation involvement
and tooth mobility.
Subject selection criteria
Inclusion criteria
To be eligible to participate in this study, a subject must
meet all of the following criteria:
 Diagnosed with H&N squamous cell carcinoma
(SCC) or a salivary gland cancer (SGC), and intends
to receive external beam RT with curative intent
(tumor eradication), with or without concomitant
chemotherapy;
OR
Diagnosed with a non-SCC, non-SGC malignancy of
the H&N region, and intends to receive RT, with or
without concomitant chemotherapy. The subject
must be expected to receive at least 4500 cGy to at
least 1 of 26 specified sites in the H&N region;
 Aged 18 years and older;
 Willing and able to provide signed and dated
consent form;
 At least 1 natural tooth remaining or expected to
remain in the mouth after completion of the pre-RT
dental extractions, if any;
 Willing to comply with all study procedures; and
 Willing to participate for the duration of the study.
After the completion of the baseline study visit, it
must be verified that the subject has received at least
one session of RT, to confirm eligibility for continued
follow-up in the study.
Exclusion criteria
A potential subject who meets any of the following
criteria will be excluded from participation in this study:
 Receiving palliative RT;
 History of prior curative RT to the H&N region to
eradicate a malignancy;
 Incarcerated at time of screening; or
 Anything that would place the subject at increased
risk or preclude the subject’s full compliance with or
completion of the study.
Study assessments
Figure 1 depicts the sequence of events in a subject’s
participation. A baseline visit is conducted before the be-
ginning of RT but after completing any recommended
pre-RT extractions and other invasive oral procedures.
Follow-up visits are conducted at 6, 12, 18, and 24 months
Fig. 1 Sequence of a subject’s participation
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procedures conducted at each study visit.
Details of study assessments, including instruments/
scales used, are as follows:
 A panoramic radiograph taken within 180 days
before the baseline study visit is evaluated to assess
the presence of intrabony devices, periapical lesions
and impacted teeth.
 Periodontal measures are collected at baseline, 12,
and 24 month visits. Probing depths and the
distance from the cemento-enamel junction to the
gingival margin are measured using a UNC 15
probe at six sites on each tooth. The clinical
attachment level is calculated by the DCC using
these two recorded measurements. The presence
of bleeding upon probing is documented at the
six periodontal probing sites. These assessmentsare obtained on all teeth other than third molars.
Additionally, at the baseline visit, a plaque score
is recorded for the Ramfjord teeth, furcation
involvement is measured using a Naber’s probe,
and tooth mobility is assessed [9]. The invasive
periodontal measures are not performed on
patients needing antibiotic prophylaxis prior to
invasive dental procedures.
 Decayed, missing, filled surfaces (DMFS) are
recorded at baseline, 6, 12, 18, and 24 month visits.
The dentition is examined for active decay, missing
teeth because of extraction and/or spontaneous
exfoliation, and teeth that have restorations. A No.
23 explorer or a No. 2A explorer is used to detect
decay. Five tooth surfaces on the posterior teeth and
four tooth surfaces on the anterior teeth are scored
for DMFS. The DMFS is also used to reconcile
newly missing teeth between study visits.
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Lalla et al. BMC Oral Health  (2017) 17:59 Page 6 of 9 Salivary flow rate is collected at baseline, 6, and
18 month visits. Participants are provided with
unflavored paraffin (gum base) and two 50 ml test
tubes. They are instructed to chew the gum base for
2 min, meanwhile expectorating saliva into one of
two test tubes. This is done as practice to
standardize the technique and stabilize the flow rate.
The same chewing/expectorating method is used for
5 min for the final flow rate assessment, timed using
a digital timer. The saliva collected in 5 min is
weighed and recorded.
 Additional assessments completed at all visits
include clinical examination of the subject’s oral
cavity for “hopeless teeth” (using criteria described
above), grading of oral mucositis using the World
Health Organization (WHO) mucositis scale [10],
inspection of both the mandible and maxilla for
exposed intraoral bone, and measurement of
maximal mouth opening using a Therabite® Range of
Motion Scale in millimeters.
 Patient-reported questionnaires are administered at
all study visits. These questionnaires collect
information on the participant’s daily oral hygiene
habits, oral pain using the UCSF Oral Cancer Pain
Scale [11], and quality of life related to their oral
health using items from the EORTC QLQ-H&N35
scale [12].
 Additional “Event visits” are conducted if a subject
has any of the following “events”: has a dental
extraction, reports spontaneous exfoliation of a
tooth, or has an area of exposed intraoral bone. Any
signs and symptoms the subject may present with at
the visit are recorded, including those related to
infection and wound healing. Additional data,
related to the event, is collected from the medical
and dental records, including radiation doses to
affected locations and the condition of the teeth
before extraction.
Statistical considerations
Sample size and power considerations
Total planned enrollment is 756 subjects across all clin-
ical sites. The primary outcome used to determine sam-
ple size is the rate of tooth loss after the end of RT.
Although ORN is an important outcome in these
patients, the relative infrequency of ORN [13] makes it
unfeasible to conduct a study with ORN as a primary
outcome measure. Tooth loss is an ideal outcome meas-
ure because it is more common than ORN, it is easily
measured, and ORN in this population often results
from post-RT dental extractions.
Previous studies found that 20 of 168 patients either
had or were recommended to have a dental extraction
after median follow-up of 7.6 months after end of H&NRT [14], and that 10 of 50 patients (20%) reported hav-
ing had an extraction or a procedure to avoid an extrac-
tion at a median follow-up of 728 days after the end of
RT, with median time of 442 days from the end of RT to
the procedure (Unpublished data, University of Con-
necticut). We also estimated that up to 30% of enrolled
participants would withdraw from study participation,
be lost to follow-up, or become deceased during 2 years
of follow-up. Based on the foregoing, we assumed 20%
of subjects would have an extraction or a procedure to
avoid an extraction by 2 years after RT, so that 756 en-
rolled subjects would yield 529 participants with 2-year
follow-up data on tooth loss and an expected 95% confi-
dence interval (around 20%) of 16.7%–23.7%, which we
deemed adequately narrow. If the actual rate of tooth
loss is lower than 20%, a 95% confidence interval will be
narrower; if the actual rate of tooth loss is higher than
20%, a 95% confidence interval will be wider. Under
these assumptions, 88–125 subjects will have a tooth-
loss event. Based on common rules of thumb, this suf-
fices to consider 8–12 predictors (risk factors) for tooth
loss [15].
Planned analyses
The study’s primary objective is descriptive so the ana-
lyses are mainly descriptive. The primary objective can
be interpreted in two ways: What fraction of subjects
had a tooth-loss event in the two years after RT? And
how many teeth were lost per year? Analyses of the
former will use time-to-event (survival) methods, where
the event is the first tooth loss. This type of analysis ac-
counts for partial follow-up. The 2-year fraction with
tooth-loss events will be estimated using the survivor
function and associated confidence interval. To estimate
the rate of teeth lost per year, each subject’s outcome is
the number of teeth they lost, analyzed using a negative
binomial model with log link and offset log follow-up
time (in years) and no predictors. This model’s intercept,
raised to the power e (the base of the natural logarithm),
estimates the rate of teeth lost per year. (The negative
binomial model allows analysis of a count outcome with
a flexible error variance. Obviously this model is in-
appropriate if many participants lose large numbers of
teeth but this seems unlikely.) Secondary analyses will
cull potential risk factors for tooth loss events and for
increased rate of tooth loss by considering them as
predictors in the regression analyses described above.
Other secondary analyses will consider the secondary
outcomes, many of which are measured at multiple
follow-up visits, so their analyses will be longitudinal, ac-
counting for the presumed correlation of a subject’s
multiple measurements.
One complication of these analyses is how a subject’s
initial number of teeth affects tooth loss. We will
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clude in the regression a flexible function of the initial
number of teeth (e.g., a 4°-of-freedom spline). A further
complication arises from subjects who have incomplete
follow-up due to death. We account for this by defining
the outcome being estimated as “rate [or chance] of
tooth loss assuming survival to 2 years”, which can be
estimated by various methods that accommodate partici-
pants with incomplete follow-up, e.g., inhomogeneous
Poisson processes or logistic regression including a flex-
ible function of follow-up time as an adjuster.
Discussion
The results of this ongoing study are expected to be valu-
able for several reasons. First, this study will definitively
document the oral and dental morbidity resulting from
high-dose RT to the H&N region. This includes the im-
pact on salivary flow, mouth opening, caries, periodontal
disease, tooth loss, and development of ORN. A better un-
derstanding of these downstream effects of RT will inform
the pre-RT dental evaluation and reinforce its importance
to all stakeholders including patients, medical and dental
providers, and third-party payers. Second, this study
should allow the identification of risk factors for adverse
oral and dental outcomes. As mentioned previously, the
pre-RT dental management of these patients varies widely
and is largely based on expert opinion. Identification of
specific risk factors will allow for evidence-based decision
making and better clinical outcomes. Thus, our findings
have the potential to lead to significant changes in clinical
practice. Third, this study provides a unique opportunity
to compare pre-RT dental management practices across a
number of different sites. An assessment of important fac-
tors, such as number of pre-RT dental extractions, dur-
ation between extractions and start of RT, and subsequent
development of ORN, in this large cohort can be highly
informative.
There are some limitations of this study design. Two
years is a relatively short follow-up period as tooth loss
may occur after this time. While a longer follow-up
period would be desirable, funding constraints did not
allow for this and it can also be challenging to follow
such medically complex patients for longer periods. Im-
portant assessments such as periodontal measurements
and salivary flow are not conducted at each follow-up
visit. These are completed at alternating follow-up visits
to reduce the length of the follow-up visits and burden
on the subject. Although the study Manual of Proce-
dures recommends that each subject should be exam-
ined by the same clinical examiner at all visits, in
practice this has been difficult to achieve due to schedul-
ing issues and staff turnover. However, all clinical exam-
iners are calibrated to strict standards for inter- and
intra-rater consistency.Recruitment presents a challenge in most clinical stud-
ies and especially in the oncology population. It has been
estimated that only about 3% of patients with cancer
participate in a clinical trial and even at some tertiary
academic centers, the rate may be below 10% [16]. A
barrier to recruitment for the present study is that in
order for the baseline visit to be conducted prior to the
start of RT, patients may need to be approached soon
after their cancer treatment plan has been determined.
At this time, patients are often emotionally fragile and
overwhelmed with details from various providers on
planned surgery, chemotherapy, and RT. In the context
of a life-threatening diagnosis, patients can be bewil-
dered about being approached for participation in an ob-
servational dental study that does not offer any direct
impact on their cancer prognosis. Indeed, as of Decem-
ber 2015, the most common reason (60%) for an
approached patient not being formally screened is that
they are “not interested/too busy”. Careful and patient
explanation of the dental and oral complications of RT,
and possible benefits of study participation, can be help-
ful, particularly if reinforced by the radiation oncologist.
It is highly desirable to have a team-based approach,
where all parties recognize and reinforce the importance
of the study and benefits of participation, to the subject
and to society. Potential benefits to the subject include
the regular and detailed monitoring of their oral and
dental status at no charge, which can facilitate the earlier
diagnosis and management of potential oral complica-
tions. Appropriate monetary compensation is also pro-
vided to subjects for their time and effort in attending
study visits. However, the study does not directly provide
or support clinical care, which may have a negative effect
on some patients’ interest in study participation.
An important aspect of recruitment is access to the
patient population. It is standard practice in the USA for
these patients to be referred to a dentist for a pre-RT
dental assessment [1]. This dental assessment may occur
at the cancer treatment site itself or at a community
dental practice. Our experience at the different clinical
sites has shown that recruitment is enhanced when the
study team works closely with the clinical dental pro-
viders receiving the clinical referral and/or the oncology
team managing the medical care of these patients. How-
ever, the pre-RT clinical dental evaluation can also be a
reason patients decline study participation. Specifically,
when the pre-RT dental evaluation by regular clinical
providers includes periodontal probing, patients have
sometimes been unwilling to then undergo the add-
itional detailed periodontal examinations conducted at
the baseline study visit by the calibrated study examiner.
The number of eligible patients also varies across sites,
with sites located in large urban centers or tertiary care
centers usually having a larger patient population.
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the strongest enrolling sites. However, a proportion of
patients at such magnet referral centers travel from a
distance for their cancer care but may receive follow-up
closer to home. This can lead to sub-optimal compliance
with the subsequent follow-up visits after treatment.
Thus, appropriate selection of patients is important. The
main barrier to recruitment at smaller centers is access
to an adequate number of eligible patients. The smaller
sites, however, also tend to have better attendance at
follow-up visits. Strategies we have adopted at sites with
lower enrollment include the establishment of a satellite
study location at a nearby healthcare facility, where en-
rollment activities and/or study visits can take place.
While this has had a modest positive impact on enroll-
ment, it does create new challenges in terms of obtain-
ing medical records from the satellite site.
An additional factor affecting recruitment is adequate
staffing, given the ongoing demands related to schedul-
ing and conducting follow-up visits as well as data man-
agement. To better optimize use of the study staff ’s
time, the amount of medications data being collected at
follow-up visits was significantly reduced after about 250
subjects had been enrolled. An analysis of the medica-
tions data collected to that point revealed that, beyond
the 6 month visit, very few subjects were using the medi-
cations being collected. Therefore, collection of detailed
medications data from medical records after that point
was determined as not being critical to achieve the main
study objectives.
Notwithstanding all of the above-mentioned recruit-
ment considerations, over 450 subjects have been en-
rolled to the study so far. Thus, this landmark study is
expected to meet its planned enrollment target and re-
sult in significant advances in the care of patients receiv-
ing RT to the H&N region.
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